|
|
||||||||


* School of Biochemistry and Immunology, Trinity College, Dublin, Ireland;
Vrije Univeriteit, Vrije, The Netherlands; and
Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The prevalence of a range of atopic diseases is rising and with respect to allergic asthma there has been an almost 2-fold increase in incidence in the past two decades (5). The rate at which the incidence of allergic disease is rising implicates a recent change in environmental influences on this process, i.e., the hygiene hypothesis (5). This hypothesis proposes that a shift in the immune system toward type 1 immunity upon early exposure to infections such as bacterial (6, 7) and viral (8) infections protects against allergic diseases by reducing the expression of Th2 cytokines generally evoked by allergens. An alternative explanation holds that certain parasitic helminth infections may protect against allergic disorders because human populations with high rates of parasitic helminth infections, which induce an immunological shift toward the "allergic" Th2 responses, have a reduced prevalence of allergic disorders (9). Schistosoma spp. are tropical helminth parasites, characteristically associated with being potent inducers of Th2 cytokine responses including eosinophilia and IgE responses (10), that have been postulated to ameliorate atopic disorders in humans (9).
Recent experimental studies have shown that mice or rats infected with rodent nematode parasites have reduced allergic responses (11, 12, 13, 14). We have previously demonstrated that Schistosoma mansoni infection protects mice from anaphylaxis through a regulatory mechanism induced by the worm (15). In this study, we have evaluated whether S. mansoni infection of mice, the mouse being the preferred animal model for studies on the immunobiology of schistosomiasis (10), altered susceptibility of the animals to OVA-induced AHR, which is also widely used as a model of human pulmonary inflammation (16). We have identified that the worm stage of S. mansoni infection modulates mice so they are refractory to AHR. This is the first formal demonstration of a mechanism that human parasitic worms use to suppress allergen-induced airway inflammation.
| Materials and Methods |
|---|
|
|
|---|
Female BALB/c mice were purchased from Harlan at 68 wk of age. Outbred male or female Tylers Original (TO) mice, also from Harlan, were obtained for egg and worm production. IL-13-deficient (IL-13/) mice were provided by Dr. A. McKenzie (Medical Research Council Laboratory of Molecular Biology, Cambridge, U.K.) and were bred in-house (17). Mice were housed in individually ventilated and filtered cages under positive pressure (Techniplast). Food and water were supplied ad libitum. Sentinel mice were screened to ensure specific pathogen-free status. All animal experiments were performed in compliance with Irish Department of Health and Children regulations.
Parasitology
A Puerto Rican strain of S. mansoni was maintained by passage in male or female outbred TO strain mice and albino Biomphalaria glabrata snails served as intermediate hosts. Female BALB/c, 68 wk of age (Harlan), were infected percutaneously with 30 mixed male and female cercariae for a conventional infection where eggs are laid (worm + egg infections), or mice were infected with 30 male cercariae for a worm infection where no eggs are present. The sex of cercariae shed from individual snails was determined by PCR as described (18). To remove worms from worm-infected mice, animals were orally treated with the schistosomicidal drug Praziquantel (Sigma-Aldrich; 100 mg/kg orally for 5 consecutive days).
Antibodies
Cell surface phenotyping was analyzed using Tricolor-conjugated anti-CD19 (6D5; Caltag Laboratories), anti-CD4 (CT-CD4; Caltag Laboratories), anti-CD8 (5H10; Caltag Laboratories), anti-F4/80 (F4/80; Caltag Laboratories), and PE-conjugated anti-CD25 (PC61 5.3; BD Pharmingen), anti-Syndecan-1 (CD138; 281-2 BD Pharmingen), anti-CD5 (Ly-1; BD Pharmingen), anti-IgM (µ-chain specific; The Jackson Laboratory), anti-CD11b (mac-1, M1/70; BD Pharmingen), anti-CCR3 (83101; R&D Systems), and FITC-conjugated anti-GL7 (GL7; BD Pharmingen). Intracellular cytokine staining was with PE-conjugated anti-IL-4 (BVD6-24G2) and FITC-conjugated anti-IL-10 (JES5-2A5) was obtained from Caltag Medisystems.
Hybridoma culturing and Ab production
Anti-IL-10R (1B1.3a), anti-CD25 (PC61 5.3) were purchased from American Type Culture Collection. The anti-CD4 (YTS 191) hybridoma was kindly provided by Prof. A. Cooke (University of Cambridge, Cambridge, U.K.) and Prof. H. Waldman (University of Oxford, Oxford, U.K.). The above hybridoma cell lines were cultured in RPMI 1640 and supernatants were precipitated in 50% ammonium sulfate followed by dialysis against Dulbeccos PBS (DPBS; pH 7.2) (Sigma-Aldrich). Ab was purified on Protein G (Sigma-Aldrich) separation columns and protein was quantified before use. All Abs were tested for endotoxin contamination and were confirmed to have <0.5 endotoxin units/mg (Chromogenic LAL). Macrophages were depleted by the treatment of mice with liposomes containing dichloromethylene bisphosphonate (clodronate liposomes), prepared as described (19). Clodronate was a gift of Roche Diagnostics.
Ag sensitization and challenge
Mice were sensitized with OVA (fraction V: Sigma-Aldrich) and airways challenged with OVA to induce pulmonary allergic inflammation and AHR (see Fig. 1). On days 1 and 14, mice received an i.p. injection of 100 µl of a sensitization solution containing 20 µg of OVA and 2 mg of Imject Alum (Pierce). Mice received a 20-min aerosol challenge with 1% OVA in DPBS from days 2830. Control mice received an aerosol of PBS.
|
1.53 endotoxin units/mg) which previously has been shown to alter the development of AHR (20). It is impossible to completely remove endotoxin from OVA preparations (20), while the addition of polymyxin B, to inactivate LPS, is also inappropriate due to direct affects of the antibiotic on cell activation (21). Therefore, every effort was made to maintain sterile procedures to minimize the endotoxin contamination in all OVA preparations. OVA was prepared using endotoxin-free reagents and all glassware and equipment were endotoxin decontaminated (0.5 mM NaOH). Endotoxin was partially removed (Detoxi-gel endotoxin removing gel columns; Pierce) and OVA preparations were extensively dialyzed against sterile DPBS (Sigma-Aldrich) using dialysis cassettes (Pierce). After these measures, the OVA used in this study had <0.5 (range 0.1860.447) endotoxin units/mg (Chromogenic LAL). Pulmonary assessment of enhanced pause (Penh)
Lung reactivity of OVA-sensitized mice was assessed using a protocol by Hamelmann et al. (22). On day 32, airway responsiveness of mice was assessed by barometric whole body plethysmography in response to a methacholine (Mch) challenge. In brief, spontaneously breathing, nonanesthetized mice were placed in the plethysmograph (EMKA Technologies) and PBS aerosol was administered to establish baseline readings over 3 min. Mch (acetyl
-methylcholine chloride; Sigma-Aldrich) was then administered by nebulization in increasing, serial 2-fold concentrations from 3.12550 mg/ml for 3 min each dose to induce bronchoconstriction. In this model, the extent of airway reactivity of individual mice was quantified as Penh. Airway responsiveness of mice was expressed as the fold increase for each concentration of Mch compared with Penh values after PBS challenge. Twenty-four hours later, mice were sacrificed by terminal anesthesia and samples were taken for further immunological analysis.
Airway conductance and dynamic compliance studies
Pulmonary conductance (GL) and compliance (Cdyn) in response to Mch were measured as described previously (23). In brief, mice were assessed on day 31 after OVA sensitization and challenge using the same protocol as outlined above. Mice were anesthetized with 105 mg/kg pentobarbitone, tracheostomized and then mechanically ventilated (EMKA Technologies) for airway assessment. A two-way connector was attached to the tracheal cannulation tube to allow inspiration and expiration via the ventilator. Breaths were stabilized at a rate of 60 breaths/min and the tidal volume was fixed at 250 µl. Increasing doses of Mch (3.125250 µg/kg) were administered i.p. and readings were taken continuously for 4 min after injection. Maximum pulmonary resistance (GL is the inverse of resistance) and compliance (Cdyn) values were taken after each dose for statistical analysis to express changes in these functional parameters as compared against saline challenge.
Bronchoalveolar lavage (BAL)
BAL fluids were collected by cannulating the trachea and lavaging lungs with 1 ml of cold PBS. Supernatant was removed for measurement of cytokines by ELISA. BAL cells were pelleted, washed, and counted for immunofluorescence staining for surface marker expression and cytospins. The numbers of eosinophils, neutrophils, lymphocytes, and macrophages was determined by performing a differential count on at least 400 cells/slide of Giemsa-stained cytospins.
Lung processing and histology
For analysis of cells by FACS, lungs were removed from the mice and digested in 1 mg/ml collagenase D (Roche Diagnostics) in RPMI 1640 with FCS for 30 min at 37°C with shaking. Lung digests were then filtered through 100-µm Falcon cell strainers (BD Biosciences) followed by three washes and further filtering through 40-µm Falcon cell strainers. In some experiments, the left lobes of the lungs, stored snap-frozen, were removed for assessment of tissue cytokines and chemokines (IL-4, IL-5, IL-13, IL-10, IFN-
, and eotaxin). Each lung lobe was homogenized using an Ultra-Turrax homogenizer (IRK-WERKE) in 800 µl of homogenization buffer (2% FCS, 0.5% cetyltrimethylammonium bromide; Sigma-Aldrich). The homogenate was microcentrifuged at 13,000 rpm for 15 min at 4°C. The supernatant was aliquoted and the tissue extract was stored at 20°C for protein estimation, cytokine analysis, and eosinophil peroxidase (EPO) assay. The protein content of tissue extracts was determined by the BCA protein estimation kit. EPO levels were determined based on a method previously described (24). The remaining lung lobes were fixed in Formalin (10% formaldehyde in 0.9% saline solution) for histological analysis. Lung sections were stained with H&E, Giemsa for eosinophils, periodic acid-Schiff (PAS) for goblet cell counts and Martius Scarlet Blue for collagen. Pulmonary collagen was quantified by differential staining, and is expressed as micrograms of collagen per milligram of lung protein, as described (25). Goblet cells were counted on PAS-stained lung sections using an arbitrary scoring system (26, 27). PAS-stained goblet cells in airway epithelium were measured double-blind using a numerical scoring system (0: <5% goblet cells; 1: 525%; 2: 2550%; 3: 5075%; 4: >75%). The sum of airway scores from each lung was divided by the number of airways examined, 2050 airways/mouse, and expressed as mucus cell score in arbitrary units.
Cell preparation
Spleens and the lung draining mediastinal lymph nodes were removed and cells were isolated for cell culture and reactivation for cytokine measurements. Single cell suspensions were prepared from spleens and mediastinal lymph nodes and depleted of erythrocytes by lysis with 0.87% ammonium chloride solution. For in vitro experiments, cells were cultured in RPMI 1640 (Invitrogen Life Technologies) supplemented with 10% (v/v) heat-inactivated FCS (Labtech), 100 mM L-glutamine (Invitrogen Life Technologies), 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen Life Technologies). Mediastinal lymph node or spleen cells were plated at 5 x 106 cells/ml. Cells were unstimulated (media) or stimulated with plate-bound anti-CD3 (clone 145-2C11) plus anti-CD28 (4 µg/ml), OVA (5200 µg/ml), in a 24-well plate (Greiner) at 37°C for 72 h. Plates were precoated with anti-CD3 mAb at 10 µg/ml for 2 h at 37°C and then washed in sterile DPBS before addition of cells. Supernatants were harvested after 72 h and cytokine levels (IL-4, IL-5, IL-13, IFN-
, IL-10, and TGF-
) were measured by ELISA. For cell proliferation analysis, cells were exposed to a range of concentrations of OVA, in triplicate wells on 96-well plates. Cultures were pulsed with 1 µCi/well [3H]thymidine (Amersham) for the last 14 h of culture. Cells were harvested with a Tomtec cell harvester and [3H]thymidine incorporation was measured by a Wallac beta counter.
Flow cytometry
Surface marker expression and intracellular phenotyping of cells was assessed by flow cytometry as described (15, 28). Cells were counted and resuspended in ice-cold FACS buffer (2% FCS, 0.05% sodium azide in PBS) at 2 x 106 cells/ml on a 96-well plate. Cells were stained with surface Abs for 30 min on ice at the recommended concentration and then washed three times in FACS buffer. For intracellular cytokine staining, unstimulated cells were incubated with Brefeldin A (10 µg/ml; Sigma-Aldrich) for 4 h. Following surface staining, cells were fixed and permeabilized using the Fix and Perm Cell Permeabilization kit (Caltag Laboratories) with the anti-cytokine Ab added upon permeabilization. Data were collected on a FACScan flow cytometer (BD Biosciences) and analyzed using CellQuest software. In all experiments, appropriate isotype controls were used to set gates and were plotted on logarithmic scales.
Various cell populations in the lung digests were identified by flow cytometry, as described (29). Lungs cells were first gated on CD19, CD4, and CD8 vs forward side scatter (FSC). Lymphocytes were identified as FSClow, side scatter (SSC)low CD19+, CD4+, CD8+. Eosinophils distinguished as SSChigh, CD19, CD4, CD8 nonautofluorescent granulocytes that stained positive for CCR3. Alveolar macrophages were characterized as CD19, CD4, CD8 mononuclear cells that were highly autofluorescent and F4/80+.
Ab and cytokine ELISA
OVA-specific serum Abs were detected by direct ELISA (25). Total serum IgE was measured using Pharmingen Abs (BD Pharmingen). Sandwich ELISAs were performed to quantify levels of specific cytokines in the supernatants from lung tissue homogenates, BAL fluid, and in vitro cell stimulation cultures. Reagents for quantification of IL-4, IL-5, IL-13, from BD Pharmingen and IL-10 and IFN-
were purchased as a DuoSet ELISA development system from R&D Systems. Total TGF-
(acidified samples) was measured by ELISA according to the manufacturers instructions (Promega). Eotaxin detection reagents were also purchased from R&D Systems. Cytokines in lung homogenates are expressed as nanograms of cytokine per milligram of lung protein.
Statistics
GraphPad Prism and GraphPad Instat software was used to analyze the data. Differences were considered significant when p < 0.05.
| Results |
|---|
|
|
|---|
To experimentally investigate whether schistosome infection modulates immune responses following exposure to an allergen schistosome, infected mice were immunized with alum-adsorbed OVA, a model-type cytokine 2-inducing allergen, and OVA-specific immunity was analyzed. Mice were exposed to a conventional S. mansoni male and female worm infection, where eggs are laid, and thus called here worm + egg infections. Worm + egg-infected mice were sensitized with OVA systemically and in the lungs during the acute (between 7 and 11 wk of infection) and chronic (between 12 and 16 wk of infection) stages of infection (Fig. 1). Spleen cells from worm + egg-infected mice immunized with OVA during acute or chronic infection both had elevated in vitro production of allergen-specific type 2 cytokines (IL-4, IL-5, and IL-13) and IL-10 compared with production of these cytokine by cells from uninfected OVA-immunized mice (Fig. 2A). The increased type 2 cytokine response in worm + egg-infected mice was associated with greater levels of OVA-specific IgE (Fig. 2B).
|
|
Schistosome worm-infected mice are resistant to OVA-induced AHR
Previously, we have shown that mice infected with schistosome male worms are completely refractory to anaphylaxis, whereas worm + egg-infected mice were only partially resistant (15). We immunized worm-infected mice with OVA, using the protocol described in Fig. 1, to address OVA-induced AHR in these animals. It is important to note that infection of mice with schistosome male worms has been shown to induce a bias toward type 2 cytokine responses (15, 18, 32); thus, worm-infected mice have elevated basal levels of IL-4, IL-5, and IL-13 before OVA challenge. Despite this type 2 cytokine bias in worm-infected mice, spleen cells from these animals, and also from uninfected mice, that were injected with PBS and not OVA, did not produce OVA-specific cytokines in vitro (Fig. 4). In contrast, spleen cells from OVA-immunized worm-infected mice had greater allergen-stimulated type 2 cytokine (IL-4, IL-5, and IL-13) production, and also had markedly elevated sera levels of OVA-specific IgE (data not shown), compared with OVA-immunized uninfected mice (Fig. 4). Interestingly, there was greater relative allergen-specific IL-10 release by spleen cells from OVA-sensitized worm-infected mice compared with IL-10 production from spleen cells from comparable treated worm + egg-infected mice (p < 0.05; Figs. 2A and 4), which is consistent with previous studies (15, 18).
|
|
Modified pulmonary type 2 response in OVA-sensitized worm-infected mice
We have addressed lung-specific responses in worm-infected mice, as in the OVA pulmonary challenge model used, the elevated AHR in sensitized mice is associated with elevations in pulmonary type 2 cytokines, eosinophil infiltration, and goblet cell hyperplasia (35). OVA-sensitized worm-infected mice had significantly elevated levels of both IL-4 and IL-13 in BAL fluid and lung homogenates (p < 0.05) compared with OVA-sensitized uninfected mice, with no differences in IFN-
levels (Fig. 6, A and B). In contrast, IL-5 levels in BAL and lung homogenates from worm-infected mice were lower than uninfected mice, with BAL IL-5 significantly reduced (p < 0.05; Fig. 6, A and B). Thus, worm-infected mice stimulated a modified type 2 cytokine response in the lungs, with IL-4 and IL-13 levels being significantly elevated whereas IL-5 was reduced. Sensitized worm-infected mice had a striking >3-fold increase in total IL-10 in both homogenates of lungs and BAL fluid, which was significantly elevated above IL-10 levels detected in lungs of sensitized but uninfected mice (p < 0.010.001; Fig. 6, A and B). OVA-specific cytokine production by the lung mediastinal lymph node cells also demonstrated the modified Th2 response, elevated IL-4 and IL-13 but reduced IL-5, in sensitized worm-infected mice compared with sensitized uninfected mice, with an associated pronounced increase in OVA-induced IL-10 (Fig. 6C). There were no differences in OVA-specific proliferation of mediastinal lymph node cells from OVA-sensitized uninfected and worm-infected mice, indicating normal Ag-induced T cell responsiveness (Fig. 6D). Similarly, lung TGF-
levels in worm-infected and uninfected OVA-sensitized mice were not different (data not shown).
|
|
We have previously demonstrated worm-infected mice are resistant to anaphylaxis through an IL-10-dependent mechanism (15). As there was elevated pulmonary IL-10 in OVA-sensitized worm-infected mice, we used an anti-IL-10R mAb to block IL-10 activity and analyzed lung function. OVA-sensitized worm-infected mice were fully susceptible to AHR when IL-10 was blocked, with significantly greater Penh values in these animals than OVA-sensitized uninfected mice at doses >12.5 mg/ml Mch (p < 0.050.001; Fig. 8A). The increase in AHR in infected mice with IL-10 blocked was associated with a restoration of OVA-induced eosinophilia in the BAL (Fig. 8B). This increase in susceptibility to AHR and development of pulmonary eosinophilia in worm-infected mice treated with anti-IL-10R mAb was associated with significant elevation (p < 0.01) in lung IL-5 levels in the mice; IL-10R mAb-treated mice had 0.46 ± 0.19 ng of IL-5/mg lung protein, vs 0.14 ± 0.08 ng of IL-5/mg lung protein in control Ig-treated mice (data are mean ± SD, n = 5; Students t test). These data show that schistosome worm infection prevents AHR in a mouse model of allergen-induced pulmonary inflammation via IL-10-dependent suppression of pulmonary eosinophilia.
|
In mice with S. mansoni worm + egg or worm-only infections, a number of IL-10-producing cells have being identified, including CD4+ cells, CD4+CD25+ regulatory cells, macrophages, and B cells (15, 36). As we were addressing a pulmonary allergic phenotype, we characterized by flow cytometry which of these different potential cellular sources of IL-10 preferentially infiltrated the lungs of worm-infected mice. We found no major difference in the percentages of CD4+ cells, CD25+ cells, or macrophages infiltrating the lungs of sensitized worm-infected vs sensitized uninfected mice (Fig. 9A). The absence of a role for CD4+ and CD25+ cells in the resistance of worm-infected mice to AHR was further corroborated by in vivo depletion studies whereby depletion of either CD4+ or CD25+ cells in worm-infected mice demonstrated that each cell population has no role in affording protection from OVA-induced AHR (Fig. 9B). Furthermore, depletion of pulmonary macrophages had no effect on the worm infection-mediated airway protection, with OVA-sensitized worm-infected mice having lower Penh values compared with uninfected mice that developed AHR (Fig. 9B).
|
Previously, we have shown that worm-infected mice are resistant to anaphylaxis via a schistosome-induced splenic IL-10-producing B cell subpopulation (15). Significantly, there was a
30% increase in the number of infiltrating B cells in the lungs of sensitized worm-infected mice when compared with sensitized uninfected mice (Fig. 10A). Following partial depletion of B cells, via anti-IgM treatment, OVA-sensitized worm-infected mice were rendered fully susceptible to AHR (Fig. 10B), suggesting that a B cell population is intrinsic in the mechanism of resistance of worm-infected mice to AHR. In fact, the airway reactivity of these mice was even more enhanced than in uninfected mice indicating the significance of B cells in the protection from pulmonary inflammation. The susceptibility of worm-infected mice to AHR after B cell depletion was associated with a restoration of eosinophil infiltration of the lungs (Fig. 10C).
|
| Discussion |
|---|
|
|
|---|
The failure of schistosome worm-infected mice to develop OVA-induced AHR was not associated with an inability of infected mice to respond to the allergen. On the contrary, cells from infected mice had normal in vitro cell proliferation to OVA and their spleen and mediastinal lymph nodes cells produced greater levels of both spleen and lung IL-4 and IL-13 than uninfected mice. Strikingly, worm-infected mice had reduced levels of total and OVA-specific IL-5 in the lungs compared with uninfected animals, suggesting a unique selective Th2 defect in the lungs. Recently, Platts-Mills et al. (37) have suggested that a "modified Th2 response" to cat allergens may explain the reduced levels of asthma in children exposed to cats. We now describe for the first time that schistosome worms induce what we have termed "a helminth-modified pulmonary type 2 response" to OVA that renders mice refractory to allergen-induced AHR. The helminth-modified pulmonary type 2 response is characterized by elevated pulmonary allergen-specific IL-4, IL-13, but reduced IL-5 and elevated IL-10. An important question is why would a worm selectively suppress pulmonary immunity? The answer may relate to the biology of the parasite infection. Humans are repeatedly reinfected with schistosomes, with new infections requiring migration of larvae through the lungs. However, established schistosome infections evoke concomitant immunity, whereby immune responses against the adult worms and the eggs cross-react with larval Ags and thereby invading new larvae killed are killed in the lungs. Interestingly, this schistosome antilarval immunity is thought to involve production of blocking IgG Ab (38), which is similar to what is proposed in the modified Th2 response to cat allergens (37). Therefore, the schistosome parasite may induce a modified pulmonary type 2 response to suppress inflammation in the lung induced by new invading larvae.
There is already evidence from field studies in Africa that schistosome infection of humans can reduce allergic responses. Schistosoma hematobium-infected school children in The Gabon have lower prevalence of skin reactivity to house dust mites than those free of this infection (39). Strikingly, when worms are removed from patients by chemotherapy there is an increase in atopy, directly establishing a link between the presence of worms and suppression of allergic responses (40). In the experimental study described here, when adult schistosome worms were killed by drug treatment the previously resistant mice became susceptible to OVA-induced AHR. Therefore, there is a requirement for the continual presence of the worm during infection to sustain a helminth-modified type 2 pulmonary response to suppress allergic inflammation. Therefore, our experimental data support the argument that the chronic down-regulation of the immune system during helminth infections evokes a regulatory environment (41), called here a helminth-modified pulmonary type 2 response, that may impart protection from allergies. However, it is important to stress that schistosome worm-only infection is a laboratory model that facilitates intimate functional analysis of modulation of immunity by the worm, in the absence of eggs. Such worm-only infections may not occur in infected humans.
In S. hematobium-infected school children, the reduced mite-specific allergic response was associated with production of parasite-specific IL-10 (42). We have shown that worm-infected mice are resistant to allergen-induced AHR via suppression of pulmonary eosinophilia via IL-10. IL-10 is a potent regulatory cytokine suppressing a range of immune-mediated responses (43). In mouse AHR models, there are various data showing a role for IL-10 in suppressing airway inflammation and AHR (44, 45, 46, 47). One of these recent studies showed that when IL-10 was administered in vivo by gene delivery it suppresses OVA-induced AHR and airway eosinophilia (47). Although our data showing worm infection-induced IL-10 also blocks AHR and airway eosinophilia unlike the gene delivery of IL-10 in worm-infected OVA-sensitized mice, there is elevated, not reduced, allergen-specific IL-4 and IL-13 cytokines and IgE, and also no alteration in cellular response to OVA. IL-10 may be a regulatory component of the helminth modified pulmonary type 2 response we describe, as pulmonary IL-5 levels are restored in worm-infected mice with IL-10 blocked in vivo.
The production of IL-10 in conventional S. mansoni male and female egg-laying infections of mice has been shown to have a central role in preventing infection-induced pathology (36, 48, 49). Indeed, IL-10 also mediates resistance of tapeworm-infected mice to experimental colitis (50). Despite worm + egg-infected mice having elevated IL-10, these animals were highly susceptible to AHR, with worm + egg-infected mice dying, even without allergen sensitization, when exposed to Mch-induced bronchoconstriction (Fig. 2). The predisposition of worm + egg-infected mice to AHR was evident in both the acute stages of infection, which is the peak of Th2 cytokine induction, and also during the chronic stages, when the parasite has down-modulated host immunity. Although worm-infected mice produce relatively more IL-10 than comparably infected worm + egg-infected mice (15, 18), the discrepancy between infection with male worm alone causing mice to be resistant to allergen-induced inflammation whereas a male and female worm and egg-laying infection exacerbated AHR is unlikely to be solely due to IL-10 levels. Worm + egg-infected mice also have the modified type 2 response in the lungs that is observed in worm-infected mice (Fig. 6; data not shown). However, the presence of marked IL-13-dependent fibrosis in the lungs (Fig. 3) of worm + egg-infected mice, and not in mice infected with male worms (data not shown), is relevant due to the effects of IL-13-induced fibrosis on lung inflammation (31). Indeed, the contradictory exacerbating or suppressive influences of schistosomes on AHR, described here, is comparable to the potential negative or positive outcomes from disease following infections with a range of other pathogens (51).
Previous experimental studies have shown that infection with various parasitic worms causes reduced allergic responses (11, 12, 13, 14). Using the rodent gastro-intestinal nematode Nippostrongylus brasiliensis, it was shown that infection suppressed allergen-induced airway eosinophilia via IL-10 from an unidentified cell source (14). It has been argued that CD4+ cells, either Th2 or regulatory, are the potential source of the worm-induced IL-10 (14). As CD4+ IL-10-producing cells generated by pathogens or genetically prepared suppress airway inflammation (52, 53), they are an attractive possible source for helminth-induced IL-10. Indeed, we have previously shown that schistosome worm infections of mice induce elevated frequencies of natural CD4+CD25+ regulatory cell and IL-10-producing CD4+ cells (15). However, depletion of CD4+ or CD25+ cells did not alter the resistance of worm-infected mice to OVA-induced AHR. Similarly, depletion of alveolar macrophages, which also produce IL-10, did not alter the worm-induced protection against AHR. Previously, we have shown B cell-IL-10 levels were significantly enhanced in worm-infected mice, with B cells having a crucial role in schistosome worm infection-mediated resistance to anaphylaxis (15) and AHR (this study). Earlier studies have already proposed that B regulatory cells or IL-10-producing B cells may function in immune-mediated inflammatory reactions (54, 55, 56). For example, in murine experimental autoimmune encephalomyelitis and collagen-induced arthritis IL-10-producing B cells have been shown to have protective function in ameliorating disease (54, 55), and such cells may also suppress intestinal inflammation (56).
Our initial studies have found no major alteration between worm + egg vs worm-only infected mice in different B cell subpopulations we have examined (B1: CD19+CD5+; B2: CD19+CD5; germinal center B cells: CD19+ GL7+; Ab-containing B cells (plasma cells and plasmablasts): syndecan-1+CD19int (57)), although both groups had elevated numbers of B cells in the lungs in comparison to uninfected mice. Worm-infected mice have increased frequencies of IL-10-producing B-1 cells in the peritoneum, an observation originally reported in worm + egg-infected mice (58). However, using worm-infected xid mice that have defective B-1 cells, we have shown that these B cells have no role in affording protection from anaphylaxis (15) or from OVA-induced AHR (data not shown). We are currently addressing the specific B cell subpopulation that is evoking this IL-10-mediated protection from pulmonary insult in worm-infected mice. Nonetheless, it is of significance that depletion of B cells disrupts the fine signaling balance in immune regulation and thus exacerbates OVA-induced pulmonary inflammation by removal of a potentially critical regulatory cell. Further studies are required to address the interplay between B cells, IL-10, and the helminth-modified pulmonary type 2 response.
In this study, we demonstrate both protective and antagonistic roles for schistosome infections of mice in an experimental test of the hygiene hypothesis (51). In marked contrast, S. mansoni worm-only infection of mice diminishes the disease effects in a model of OVA-induced AHR via induction of what we have termed a helminth-modified pulmonary type 2 response. These data highlight the important influence of the helminth parasite S. mansoni and its significance in allergic disorders. Importantly, this is the first formal demonstration of protection by a pathogen of humans in a mouse model of allergic pulmonary disease.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by the Wellcome Trust and Science Foundation Ireland. ![]()
2 Address correspondence and reprint requests to Dr. Padraic G. Fallon, School of Biochemistry and Immunology, Trinity College, Dublin, Ireland. E-mail address: pfallon{at}tcd.ie ![]()
3 Abbreviations used in this paper: AHR, airway hyperresponsiveness; DPBS, Dulbeccos PBS; Penh, enhanced pause; Mch, methacholine; GL, pulmonary resistance; Cdyn, pulmonary compliance; BAL, bronchoalveolar lavage; EPO, eosinophil peroxidase; PAS, periodic acid-Schiff; FSC, forward side scatter; SSC, side scatter. ![]()
Received for publication July 19, 2005. Accepted for publication October 24, 2005.
| References |
|---|
|
|
|---|
B-
/NF-
B and ERK1/2 pathways and adhesion. J. Biol. Chem. 280: 14264-14271. This article has been cited by other articles:
![]() |
M. Jiz, J. F. Friedman, T. Leenstra, B. Jarilla, A. Pablo, G. Langdon, S. Pond-Tor, H.-W. Wu, D. Manalo, R. Olveda, et al. Immunoglobulin E (IgE) Responses to Paramyosin Predict Resistance to Reinfection with Schistosoma japonicum and Are Attenuated by IgG4 Infect. Immun., May 1, 2009; 77(5): 2051 - 2058. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. G. Pacifico, F. A. V. Marinho, C. T. Fonseca, M. M. Barsante, V. Pinho, P. A. Sales-Junior, L. S. Cardoso, M. I. Araujo, E. M. Carvalho, G. D. Cassali, et al. Schistosoma mansoni Antigens Modulate Experimental Allergic Asthma in a Murine Model: a Major Role for CD4+ CD25+ Foxp3+ T Cells Independent of Interleukin-10 Infect. Immun., January 1, 2009; 77(1): 98 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mulvenna, B. Hamilton, S. H. Nagaraj, D. Smyth, A. Loukas, and J. J. Gorman Proteomics Analysis of the Excretory/Secretory Component of the Blood-feeding Stage of the Hookworm, Ancylostoma caninum Mol. Cell. Proteomics, January 1, 2009; 8(1): 109 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Smith, N. E. Mangan, C. M. Walsh, R. E. Fallon, A. N. J. McKenzie, N. van Rooijen, and P. G. Fallon Infection with a Helminth Parasite Prevents Experimental Colitis via a Macrophage-Mediated Mechanism J. Immunol., April 1, 2007; 178(7): 4557 - 4566. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |